$NUVB
Nuvation Bio Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004093 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.607M $5.669M $740.0K
YoY Change 71.72% 666.08%
% of Gross Profit
Research & Development $22.00M $17.12M $8.627M
YoY Change 135.57% 98.47%
% of Gross Profit
Depreciation & Amortization $43.00K $70.00K $30.00K
YoY Change -57.0% 133.33% 200.0%
% of Gross Profit
Operating Expenses $29.61M $22.79M $11.55M
YoY Change -30.84% 97.39%
Operating Profit -$22.79M -$11.55M
YoY Change 97.39%
Interest Expense $766.0K $857.0K $0.00
YoY Change 29.83%
% of Operating Profit
Other Income/Expense, Net $3.709M $812.0K $512.0K
YoY Change -3809.0% 58.59%
Pretax Income -$25.13M -$21.98M -$11.03M
YoY Change -38.58% 99.19%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$25.13M -$21.98M -$11.03M
YoY Change -38.58% 99.19%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11
Diluted Earnings Per Share -$119.5K -$106.1K -$39.54K
COMMON SHARES
Basic Shares Outstanding 217.8M 217.8M
Diluted Shares Outstanding 207.1K

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $765.4M $791.8M $1.300M
YoY Change 254.76% 60806.46%
Cash & Equivalents $132.4M $344.6M $8.322M
Short-Term Investments $633.0M $447.2M $88.40M
Other Short-Term Assets $3.642M $3.014M $400.0K
YoY Change -4.16% 653.5%
Inventory
Prepaid Expenses $3.642M
Receivables
Other Receivables
Total Short-Term Assets $772.1M $796.6M $1.700M
YoY Change 249.86% 46759.53%
LONG-TERM ASSETS
Property, Plant & Equipment $786.0K $758.0K $700.0K
YoY Change 14.24% 8.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $421.0K $421.0K $143.8M
YoY Change 5.25% -99.71%
Other Assets
YoY Change
Total Long-Term Assets $4.078M $1.179M $143.8M
YoY Change 267.72% -99.18%
TOTAL ASSETS
Total Short-Term Assets $772.1M $796.6M $1.700M
Total Long-Term Assets $4.078M $1.179M $143.8M
Total Assets $776.2M $797.8M $145.5M
YoY Change 249.95% 448.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.925M $5.163M $700.0K
YoY Change 80.79% 637.57%
Accrued Expenses $12.14M $8.145M $300.0K
YoY Change 177.1% 2615.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.93M $13.31M $1.000M
YoY Change 158.36% 1230.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $13.23M $15.12M $100.0K
YoY Change 6514.5% 15017.0%
Total Long-Term Liabilities $13.23M $15.12M $0.00
YoY Change 6514.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.93M $13.31M $1.000M
Total Long-Term Liabilities $13.23M $15.12M $0.00
Total Liabilities $30.15M $28.43M $1.000M
YoY Change 349.52% 2742.5%
SHAREHOLDERS EQUITY
Retained Earnings -$162.8M $137.7M
YoY Change 114.34%
Common Stock $910.0M $906.6M
YoY Change 214.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $746.0M $769.4M $91.85M
YoY Change
Total Liabilities & Shareholders Equity $776.2M $797.8M $145.5M
YoY Change 249.95% 448.31%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$25.13M -$21.98M -$11.03M
YoY Change -38.58% 99.19%
Depreciation, Depletion And Amortization $43.00K $70.00K $30.00K
YoY Change -57.0% 133.33% 200.0%
Cash From Operating Activities -$23.48M -$13.15M -$490.0K
YoY Change -34.84% 2583.27% -96.74%
INVESTING ACTIVITIES
Capital Expenditures -$135.0K -$29.00K $20.00K
YoY Change -10.0% -245.0% -93.75%
Acquisitions
YoY Change
Other Investing Activities -$189.1M -$91.69M -$143.8M
YoY Change -357.07% -36.21% 17.09%
Cash From Investing Activities -$189.3M -$91.72M -$143.8M
YoY Change -357.75% -36.19% 16.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 538.0K -32.00K 145.6M
YoY Change -104.32% -100.02% 1.2%
NET CHANGE
Cash From Operating Activities -23.48M -13.15M -490.0K
Cash From Investing Activities -189.3M -91.72M -143.8M
Cash From Financing Activities 538.0K -32.00K 145.6M
Net Change In Cash -212.2M -104.9M 1.340M
YoY Change -950.53% -7928.51% -76.61%
FREE CASH FLOW
Cash From Operating Activities -$23.48M -$13.15M -$490.0K
Capital Expenditures -$135.0K -$29.00K $20.00K
Free Cash Flow -$23.35M -$13.12M -$510.0K
YoY Change -34.95% 2472.35% -96.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
nuvb Issuance Costs From Business Merger In Accounts Payable And Accrued Expenses
IssuanceCostsFromBusinessMergerInAccountsPayableAndAccruedExpenses
0
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001811063
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39351
dei Entity Registrant Name
EntityRegistrantName
Nuvation Bio Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0862255
dei Entity Address Address Line1
EntityAddressAddressLine1
1500 Broadway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1401
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
332
dei Local Phone Number
LocalPhoneNumber
208-6102
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
217787632
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
344631000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29755000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3014000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
914000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
447153000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
185997000
CY2021Q3 nuvb Interest Receivable On Marketable Securities Current
InterestReceivableOnMarketableSecuritiesCurrent
1814000
CY2020Q4 nuvb Interest Receivable On Marketable Securities Current
InterestReceivableOnMarketableSecuritiesCurrent
1092000
CY2021Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
0
CY2020Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
2925000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
796612000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
220683000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
758000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
688000
CY2021Q3 nuvb Lease Security Deposit Noncurrent
LeaseSecurityDepositNoncurrent
421000
CY2020Q4 nuvb Lease Security Deposit Noncurrent
LeaseSecurityDepositNoncurrent
421000
CY2021Q3 us-gaap Assets
Assets
797791000
CY2020Q4 us-gaap Assets
Assets
221792000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5163000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2171000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8145000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4380000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13308000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6551000
CY2021Q3 nuvb Warrant Liability
WarrantLiability
14936000
CY2020Q4 nuvb Warrant Liability
WarrantLiability
0
CY2021Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
181000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
157000
CY2021Q3 us-gaap Liabilities
Liabilities
28425000
CY2020Q4 us-gaap Liabilities
Liabilities
6708000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1060000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1174094678
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
217776232
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
217776232
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
149042155
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
149042155
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
906647000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
289482000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
137669000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
75955000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
388000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1557000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
769366000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
215084000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
797791000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
221792000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17122000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8627000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47035000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23267000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5669000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2919000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16674000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6516000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
22791000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
11546000
us-gaap Operating Expenses
OperatingExpenses
63709000
us-gaap Operating Expenses
OperatingExpenses
29783000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22791000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11546000
us-gaap Operating Income Loss
OperatingIncomeLoss
-63709000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29783000
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
847000
CY2020Q3 us-gaap Interest Income Other
InterestIncomeOther
445000
us-gaap Interest Income Other
InterestIncomeOther
2061000
us-gaap Interest Income Other
InterestIncomeOther
1486000
CY2021Q3 us-gaap Professional Fees
ProfessionalFees
170000
CY2020Q3 us-gaap Professional Fees
ProfessionalFees
52000
us-gaap Professional Fees
ProfessionalFees
454000
us-gaap Professional Fees
ProfessionalFees
168000
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-125000
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-332000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2021Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-10000
CY2020Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-119000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-56000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
86000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
812000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
512000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1995000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1404000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21979000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11034000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-61714000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28379000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11384000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62883000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26979000
CY2021Q1 nuvb Retroactive Application Of Recapitalization Of Preferred Stock Due To Business Combination Transaction Value
RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue
267521000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
215084000
CY2021Q1 nuvb Issuance And Exchange Of Common Stock Net Of Issuance Cost Upon Business Combination Transaction Value
IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue
606885000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-21979000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11034000
us-gaap Net Income Loss
NetIncomeLoss
-61714000
us-gaap Net Income Loss
NetIncomeLoss
-28379000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
207101
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
91771
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
193730
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
88755
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-21979000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11034000
us-gaap Net Income Loss
NetIncomeLoss
-61714000
us-gaap Net Income Loss
NetIncomeLoss
-28379000
CY2021Q3 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-369000
CY2020Q3 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-350000
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-1169000
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
1400000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22348000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3787000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1566000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-20402000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-576000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
806344000
CY2021Q2 nuvb Issuance Costs Related To Prior Issuance And Exchange Of Common Stock Upon The Merger
IssuanceCostsRelatedToPriorIssuanceAndExchangeOfCommonStockUponTheMerger
-195000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
190000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2153000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19333000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-224000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
788935000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2749000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-21979000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-369000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
769366000
CY2020Q1 nuvb Retroactive Application Of Recapitalization Of Preferred Stock Due To Business Combination Transaction Value
RetroactiveApplicationOfRecapitalizationOfPreferredStockDueToBusinessCombinationTransactionValue
141864000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
117748000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-332000
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
722000
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-390000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
340000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8746000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
819000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
110161000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
389000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8599000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
931000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
102882000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
348000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11034000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-350000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
91846000
us-gaap Profit Loss
ProfitLoss
-61714000
us-gaap Profit Loss
ProfitLoss
-28379000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3787000
us-gaap Share Based Compensation
ShareBasedCompensation
6468000
us-gaap Share Based Compensation
ShareBasedCompensation
1077000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
141000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
76000
nuvb Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
-2989000
nuvb Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
-449000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-56000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
86000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1788000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
333000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3034000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1700000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3461000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1379000
nuvb Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
24000
nuvb Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
135000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44708000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23592000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
354848000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7233000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
89590000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
32788000
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
0
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
2508000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
147000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
118000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-265405000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27945000
us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
624769000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
220000
us-gaap Stock Issued1
StockIssued1
3787000
nuvb Issuance Costs From Business Merger In Accounts Payable And Accrued Expenses
IssuanceCostsFromBusinessMergerInAccountsPayableAndAccruedExpenses
658000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
500000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
624989000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
500000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
314876000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4853000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29755000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3469000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
344631000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8322000
nuvb Purchase Of Property And Equipment Included In Accounts Payable
PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable
66000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Nature of Operations</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nuvation Bio Inc. and subsidiaries (“Nuvation Bio”), a Delaware corporation, is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio was incorporated on March 20, 2018 (inception date) and has offices in New York and San Francisco.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 10, 2021, (the “Closing Date”), Nuvation Bio Inc., a Delaware corporation (“Legacy Nuvation Bio”), Panacea Acquisition Corp. (“Panacea”), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (“Merger Sub”) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 20, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (“Merger Agreement”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the “Merger”) and, collectively with the other transactions described in the Merger Agreement. On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the “Company” or “Nuvation Bio”).</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p>
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
137700000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44700000
CY2021Q3 nuvb Cash And Cash Equivalents And Marketable Securities
CashAndCashEquivalentsAndMarketableSecurities
791800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the periods. Accordingly, actual results could differ from those estimates and those differences could be significant.</span>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of government and corporate bonds, with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.</span></p>
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5787472
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.50
us-gaap Sale Of Stock Description Of Transaction
SaleOfStockDescriptionOfTransaction
the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company’s common stock.
nuvb Cash At Bank And Cash Held In Trust Account
CashAtBankAndCashHeldInTrustAccount
144642000
nuvb Proceeds From Pipe Investment And Forward Purchase Agreement
ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement
501550000
nuvb Payment Of Underwriter Fees And Other Offering Costs
PaymentOfUnderwriterFeesAndOtherOfferingCosts
-23913000
nuvb Payment To Common Stockholders Due To Exercised Right To Redeem Shares
PaymentToCommonStockholdersDueToExercisedRightToRedeemShares
-32000
nuvb Proceeds From Business Combination Net
ProceedsFromBusinessCombinationNet
622247000
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
312000
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Financial Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities
-601000
CY2021Q3 nuvb Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Warrant Liability
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability
-15268000
CY2021Q3 nuvb Panacea Equity At Effective Time
PanaceaEquityAtEffectiveTime
606690000
CY2021Q1 nuvb Share Outstanding Prior To Business Combination
ShareOutstandingPriorToBusinessCombination
18456250
CY2021Q1 nuvb Redemption Of Share Prior To Business Combination
RedemptionOfSharePriorToBusinessCombination
-3350
CY2021Q1 nuvb Conversion Of Shares Related To Merger
ConversionOfSharesRelatedToMerger
0
CY2021Q1 nuvb Business Combination Common Stock Shares Outstanding
BusinessCombinationCommonStockSharesOutstanding
18452900
CY2021Q1 nuvb Shares Issued Pursuant To Pipe Financing
SharesIssuedPursuantToPIPEFinancing
47655000
CY2021Q1 nuvb Shares Issued Pursuant To Forward Purchase
SharesIssuedPursuantToForwardPurchase
2500000
CY2021Q1 nuvb Issuance Of Shares Upon Business Combination
IssuanceOfSharesUponBusinessCombination
68607900
CY2021Q1 nuvb Business Combination Conversion Of Common Stock
BusinessCombinationConversionOfCommonStock
23299337
CY2021Q1 nuvb Conversion Of Founder Shares
ConversionOfFounderShares
0
CY2021Q1 nuvb Number Of Common Shares Outstanding After Business Combination
NumberOfCommonSharesOutstandingAfterBusinessCombination
217650055
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
447153000
CY2021Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
14936000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
185997000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
446765000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
447153000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
388000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
184440000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
185997000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1557000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
86000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
388000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1821000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
201067000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
231158000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
432225000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
3000000.0
us-gaap Adjustment For Amortization
AdjustmentForAmortization
400000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
421000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1113000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1486000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-56000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1557000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2749000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
348000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6468000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1077000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
6.09
CY2021Q3 us-gaap Market Risk Benefit Change In Fair Value Gain Loss
MarketRiskBenefitChangeInFairValueGainLoss
100000
us-gaap Market Risk Benefit Change In Fair Value Gain Loss
MarketRiskBenefitChangeInFairValueGainLoss
300000
us-gaap Fair Value Equity Level1 To Level2 Transfers Description
FairValueEquityLevel1ToLevel2TransfersDescription
There were no transfers between Levels 1, 2 or 3 during the period ended September 30, 2021
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
14936000
CY2021Q3 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2021Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0

Files In Submission

Name View Source Status
0000950170-21-004093-index-headers.html Edgar Link pending
0000950170-21-004093-index.html Edgar Link pending
0000950170-21-004093.txt Edgar Link pending
0000950170-21-004093-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nuvb-20210930.htm Edgar Link pending
nuvb-20210930.xsd Edgar Link pending
nuvb-20210930_cal.xml Edgar Link unprocessable
nuvb-20210930_def.xml Edgar Link unprocessable
nuvb-20210930_htm.xml Edgar Link completed
nuvb-20210930_lab.xml Edgar Link unprocessable
nuvb-20210930_pre.xml Edgar Link unprocessable
nuvb-ex31_1.htm Edgar Link pending
nuvb-ex31_2.htm Edgar Link pending
nuvb-ex32_1.htm Edgar Link pending
nuvb-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending